Kopra Bio
Genetically engineered viruses that teach your immune system to kill…
San Francisco, United States · Founded 2024 · $600K raised
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2024
- Website
- kopra.bio
- Total Funding
- $600K
- Last Round
- $100K GrantJan 2025
- Rounds
- 2
About
Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.
Summary
Kopra Bio is a Biotech company based in San Francisco, United States, founded in 2024. It has raised $600K in total across 2 rounds, most recently a $100K Grant round in Jan 2025. Investors include Y Combinator Continuity Fund and Pioneer Fund.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...